Mechanistic modeling explains the production dynamics of recombinant adeno-associated virus with the baculovirus expression vector system.

ABSTRACT: Current manufacturing processes for recombinant adeno-associated viruses (rAAVs) have less-than-desired yields and produce significant amounts of empty capsids. The increasing demand and the high cost of goods for rAAV-based gene therapies motivate development of more efficient manufacturing processes. Recently, the US Food and Drug Administration (FDA) approved the first rAAV-based gene therapy product manufactured in the baculovirus expression vector system (BEVS), a technology that demonstrated production of high titers of full capsids. This work presents a first mechanistic model describing the key extracellular and intracellular phenomena occurring during baculovirus infection and rAAV maturation in the BEVS. The model predictions are successfully validated for in-house and literature

SUBMITTER: Destro F 

PROVIDER: S-EPMC10512016 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature